Published

Behavioral and neuronal effects of psilocybin in mice

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2025-12-31
Source: OpenAlex
DOI: 10.1016/j.nsa.2025.106575
PubMed: Unavailable

Authors

C. Weber F. Sellitti L. Ziming J. von Arx L.D. Simmler

Watch author

Topics and keywords

psilocybin Pharmacology Animal Study Toxicity Animal Study Neuroscience Psilocybin Central nervous system Chemistry Medicine Pharmacology Hallucinogen Midbrain Biology Neural activity Psychedelics and Drug Studies Forensic Toxicology and Drug Analysis Paranormal Experiences and Beliefs

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Behavioral and neuronal effects of psilocybin in mice2025-12-31

Related papers

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental modelsFrontiers in Systems Neuroscience · 2025-08-04 Addressing the Implicit Impacts of Sexual Trauma: An Exploration of Somatic Experiencing as an Adjunct to Psilocybin-Assisted TherapyNational University System Repository (National University System) · 2021-04-30 Is Psilocybin an Effective Treatment to Reduce Depression and Anxiety in Cancer Patients with a Diagnosis of an Anxiety Disorder, Mood Disorder, And/Or Stress Disorder?Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · 2019-12-31 Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a WorkshopNational Academies Press (US), Washington (DC) · 2022-08-31 The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationClinicalTrials.gov · 2025-12-23 An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)ClinicalTrials.gov · 2024-08-08 The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.ClinicalTrials.gov · 2022-10-24